Evoke Pharma, Inc.
EVOK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.10 | -0.05 | 0.04 | 0.09 |
| FCF Yield | -4.11% | -8.51% | -14.23% | -18.88% |
| EV / EBITDA | -6.06 | 0.20 | 0.40 | 1.75 |
| Quality | ||||
| ROIC | -13.42% | -16.40% | -11.85% | -9.79% |
| Gross Margin | 97.62% | 95.53% | 98.65% | 96.42% |
| Cash Conversion Ratio | 0.45 | 0.36 | 0.76 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | 49.69% | 53.03% | 58.70% | 59.86% |
| Free Cash Flow Growth | 7.62% | 43.36% | 19.56% | -51.46% |
| Safety | ||||
| Net Debt / EBITDA | 6.27 | 4.79 | 6.32 | 7.91 |
| Interest Coverage | -9.03 | -12.51 | -10.56 | -9.47 |
| Efficiency | ||||
| Inventory Turnover | 0.17 | 0.26 | 0.08 | 0.27 |
| Cash Conversion Cycle | -2,859.86 | -1,511.77 | -4,790.85 | -1,146.39 |